Alimera Sciences
Manufacturing · Georgia, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6310 Town Sq Ste 400, Alpharetta, Georgi...Phone Number
(678) 990-5740Website
www.alimerasciences.comRevenue
$90.2 MillionStock Symbol
ALIMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Alimera Sciences
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations.Explore more
Alimera Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alimera Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alimera Sciences launches new products
Click to see if Alimera Sciences had a recent Job posting/layoffs
Check out if Alimera Sciences is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Alimera Sciences
Funding: Get notified immidiatlly once Alimera Sciences has new funding data
Check if Alimera Sciences has recently received funding, and reach out quickly before it becomes old news!
Alimera Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Alimera Sciences recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Alimera Sciences as Masked Content
Find 3 more new buyers
Compare Similar Companies to Alimera Sciences
Compare insights from companies similar to Alimera Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Alimera Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alimera Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alimera Sciences.
Alimera Sciences financials insights
Gather financial insights about Alimera Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Stock Offering
$72M
2012
Share Placement
$40M
2014
Share Placement
$37.5M
Debt
$35M
2016
Stock Offering
$26.5M
2018
Debt
$40M
2019
Share Placement
$20M
2020
Debt
$45M
Debt
$1M
Alimera Sciences Tech Stack
A closer look at the technologies used by Alimera Sciences
Most Recent Scoops
Person-Based
Earnings
Funding, Operations
Earnings
Asset Management
Earnings
Product Management
Earnings
Risk
Alimera Sciences News & Media
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (Nasdaq: ALIM).Alimera Sciences Takes Legal Action Against ANI Pharmaceuticals to Enforce Merger Agreement
ATLANTA--(BUSINESS WIRE)--Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced that it has filed a lawsuit in the Delaware Court of Chancery (the “Court”) to compel ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI”) to fulfill its contractual obligation to close the transaction contemplated by the companies’ previoBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
BALA CYNWYD, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
We are investigating the fairness of the proposed sale of Alimera Sciences to ANI Pharmaceuticals for $5.50 per share in cash, plus a CVR.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alimera Sciences
Sign Up For FreeTo access detailed company insights
Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging population... Read More
